Been a long time coming. Been buying when it was $2-5 a share. Hopefully, my years of patience will pay off after years of setbacks. Let's hope the FDA doesn't come up with some lame reason to delay or reject the application. I don't have much faith in the FDA's reasoning at times.
The PI contains a black box warning. They also found two cases of lung cancer in the drug group none in the placebo arm. This seems a risky proposition when it is used in a larger post approval situation more issues can and will appear. Good luck to those that own stock.
2 cases out of 6000+ trial participants, lower incidence than general population and they were long time smokers. MNKD not recommended for smokers or anyone with respiratory issues per company request and FDA label.
This product has enormous potential. It should change the way diabetes is treated. The oral agents do more harm than good in that they delay the use of insulin. That delay is doing more harm than any other treatment paradigm in the entire world of healthcare.
A very disappointing stock. Went down post Ad-com, then went down further post FDA approval, now really goes down post Sanofi commercialization plan (which was unimpressive). I held too much faith in Al Mann.